Antiepileptic drugs and markers of vascular risk

Current Treatment Options in Neurology

Volumn 12, Issue 4, 2010, Pages 300-308

  LoPinto Khoury, Carla ^a   Mintzer, Scott ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; C REACTIVE PROTEIN; CARBAMAZEPINE; CHOLESTEROL; ENZYME INDUCING AGENT; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ABDOMINAL OBESITY; ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; DISEASE MARKER; ENZYME INDUCTION; ENZYME INHIBITION; EPIDEMIOLOGICAL DATA; EPILEPSY; ESSENTIAL TREMOR; GLUCOSE INTOLERANCE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; VASCULAR DISEASE;

EID: 77956367251     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0080-y     Document Type: Review

References (53)

1. Annegers JF, Hauser WA, Shirts SB: Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 1984, 25:699-704.
2. Nilsson L, Tomson T, Farahmand BY, et al.: Causespecific mortality in epilepsy: A cohort study of more than 9, 000 patients once hospitalized for epilepsy. Epilepsia 1997, 38:1062-1068.
3. Ding D, Wang W, Wu J, et al.: Premature mortality in people with epilepsy in rural China: A prospective study. Lancet Neurol 2006, 5:823-827.
4. Satishchandra P, Chandra V, Schoenberg BS: Casecontrol study of associated conditions at the time of death in patients with epilepsy. Neuroepidemiology 1988, 7:109-114.
5. Gaitatzis A, Carroll K, Majeed A, Sander JW: The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004, 45:1613-1622.
6. Cockerell OC, Johnson AL, Sander JW, et al.: Mortality from epilepsy: Results from a prospective population-based study. Lancet 1994, 344:918-921.
7. Muuronen A, Kaste M, Nikkila EA, Tolppanen EM: Mortality from ischaemic heart disease among patients using anticonvulsive drugs: A casecontrol study. Br Med J (Clin Res Ed) 1985, 291:1481-1483.
8. Nakken KO, Kornstad S: Do males 30-50 years of age with chronic epilepsy and on long-term anticonvulsant medication have lower-than-expected risk of developing coronary heart disease? Epilepsia 1998, 39:326-330.
9. Gibbons GF: The role of cytochrome P450 in the regulation of cholesterol biosynthesis. Lipids 2002, 37:1163-1170.
10. Kandutsch AA, Chen HW: Inhibition of cholesterol synthesis by oxygenated sterols. Lipids 1978, 13:704-707.
11. Franzoni E, Govoni M, D'Addato S, et al.: Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia 1992, 33:932-935.
12. Eiris JM, Lojo S, Del Rio MC, et al.: Effects of longterm treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995, 45:1155-1157.
13. Eirís J, Novo-Rodríguez MI, Del Río M, et al.: The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000, 41:1-7.
14. Castro-Gago M, Novo-Rodriguez MI, Blanco-Barca MO, et al.: Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol 2006, 21:48-53.
15. Verrotti A, Domizio S, Angelozzi B, et al.: Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997, 33:242-245.
16. Verrotti A, Basciani F, Domizio S, et al.: Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998, 19:364-367.
17. Voudris KA, Attilakos A, Katsarou E, et al.: Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006, 70:211-217.
18. Demircioglu S, Soylu A, Dirik E: Carbamazepine and valproic acid: Effects on the serum lipids and liver functions in children. Pediatr Neurol 2000, 23:142-146.
19. Nikolaos T, Stylianos G, Chryssoula N, et al.: The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004, 10:MT50-MT52.
20. Aggarwal A, Singh V, Batra S, et al.: Effect of carbamazepine therapy on serum lipids in children with partial epilepsy. Pediatr Neurol 2009, 40:94-97.
21. Bramswig S, Sudhop T, Luers C, et al.: Lipoprotein (a) concentration increases during treatment with carbamazepine. Epilepsia 2003, 44:457-460.
22. Isojarvi JI, Pakarinen AJ, Myllyla VV: Serum lipid levels during carbamazepine medication. A prospective study. Arch Neurol 1993, 50:590-593.
23. Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI: Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 1985, 28:615-618.
24. Calandre EP, Sinues Porta B, Garcia de la Calzada D: The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients. Epilepsia 1992, 33:154-157.
25. Mintzer S, Skidmore CT, Abidin CJ, et al.: Effects of antiepileptic drugs on lipids, homocysteine, and Creactive protein. Ann Neurol 2009, 65:448-456. This study directly compared the effects of inducing AEDs on various serologic markers to those of non-inducing AEDs. This is the first study to examine CRP in patients with epilepsy or in any AED-treated population.
26. Sonmez FM, Demir E, Orem A, et al.: Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 2006, 21:70-74.
27. Reddy MN: Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med 1985, 180:359-363.
28. Isojarvi JI, Pakarinen AJ, Rautio A, et al.: Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994, 35:1217-1220.
29. Calandre EP, Rodriquez-Lopez C, Blazquez A, Cano D: Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 1991, 83:250-253.
30. The Emerging Risk Factors Collaboration: Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
31. Miller M, Burgan RG, Osterlund L, et al.: A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler Thromb Vasc Biol 1995, 15:2151-2156.
32. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
33. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
34. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14, 719 initially healthyAmericanwomen. Circulation 2003, 107:391-397.
35. Tan TY, Lu CH, Chuang HY, et al.: Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009, 50:1579-1586. This study measured CA-IMT in patients on long-term AED therapy. Although limited by lack of data on individual AEDs, it clearly links AED use with the development of atherosclerosis.
36. McIlroy SP, Dynan KB, Lawson JT, et al.: Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002, 33:2351-2356.
37. Karabiber H, Sonmezgoz E, Ozerol E, et al.: Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 2003, 25:113-115.
38. Apeland T, Mansoor MA, Strandjord RE: Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001, 47:27-35.
39. Belcastro V, Striano P, Gorgone G, et al.: Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia 2010, 51:274-279. This cross-sectional study confirms earlier findings of HCY elevations with enzyme-inducing drugs and also makes a new association between elevated HCY and the newergeneration, weakly enzyme-inducing agents oxcarbazepine and topiramate.
40. Verrotti A, Pascarella R, Trotta D, et al.: Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 2000, 41:253-257.
41. Attilakos A, Papakonstantinou E, Schulpis K, et al.: Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res 2006, 71:229-232.
42. Gidal BE, Tamura T, Hammer A, Vuong A: Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 2005, 64:161-166.
43. Huemer M, Ausserer B, Graninger G, et al.: Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia 2005, 46:1677-1683.
44. Jallon P, Picard F: Bodyweight gain and anticonvulsants: A comparative review. Drug Saf 2001, 24:969-978.
45. Kim JY, Lee HW: Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007, 48:1366-1370.
46. Verrotti A, Manco R, Agostinelli S, et al.: The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010, 51:268-273.
47. Pylvanen V, Knip M, Pakarinen AJ, et al.: Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003, 60:571-574.
48. O'Leary DH, Polak JF, Kronmal RA, et al.: Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
49. Lorenz MW, von Kegler S, Steinmetz H, et al.: Carotid intima-media thickening indicates a higher vascular risk across a wide age range: Prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006, 37:87-92.
50. Silvestrini M, Cagnetti C, Pasqualetti P, et al.: Carotid wall thickness and stroke risk in patients with asymptomatic internal carotid stenosis. Atherosclerosis 2010 Jan 4 (Epub ahead of print).
51. Schwaninger M, Ringleb P, Annecke A, et al.: Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol 2000, 247:687-690.
52. Hamed SA, Hamed EA, Hamdy R, Nabeshima T: Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 2007, 74:183-192.
53. Erdemir A, Cullu N, Yis U, et al.: Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009, 31:713-716.